Ken Chang

Director, Clinical Biomarkers
Daiichi Sankyo
Ken Chang
Ken CN Chang is Director of Clinical Biomarkers at Daiichi Sankyo Inc.  His main focus is on the clinical genomics biomarkers, including patient-selection biomarkers, mostly supporting oncology clinical trials.  Prior to Daiichi Sankyo he worked at Merck for 6 years in a similar capacity with emphasis on the analytical validation and development of clinical trial assays and companion diagnostics.  Prior to Merck, he also worked at Wyeth Research and Pfizer Inc. for combined 17 years as principal investigator/drug discovery team leader in various disease areas and as the genomics core lab director.  His research interests and expertise include clinical biomarker assay development and validation, target identification/target validation using gene expression profiling technologies, DNA structure conformation, DNA replication and repair mechanisms, chemical carcinogenesis and mutagenesis, as well as anti-cancer/anti-viral drug discovery.


February 20 2020, 11:20
 - 11:50
Development Of A Novel Next-Generation Sequencing (NGS)-Based Assay For Measurable Residual Disease (MRD) In FLT3- ITD AML And Its Potential Clinical Applications

Other Speakers